About Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone
Program Title
iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone
Focus on Targeted CRF1 Receptor Antagonism and Novel Mechanism-of-Action
(MOA) for Optimizing Clinical Outcomes in Pediatric and Adult Patients with CAH
Program Medium
Internet-based program
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period March 1, 2026 through March 1, 2028, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view the activity, totaling 4.5 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.
Estimated Time to Complete Educational Activity
4.5 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.
Course Overview
In this web-based program, physicians will learn how recent developments in novel targets and treatments have advanced the management of congenital adrenal hyperplasia (CAH).
Release Date
March 1, 2026
Expiration Date
March 1, 2028
Intended Audience
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with congenital adrenal hyperplasia, including endocrinologists, pediatric endocrinologists, genetic specialists, family medicine specialists, pediatricians, physician associates, and related clinicians.
Registration
Participation in this activity is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
This activity is supported by an independent medical education grant from Neurocrine Biosciences.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Chan Medical School, Office of Continuing Medical Education designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Richard Auchus, MD, PhD
Professor of Pharmacology and Internal Medicine
Division of Metabolism, Endocrinology, and Diabetes
University of Michigan
Ann Arbor, MI
Consultant or advisor for: Adrenas Therapeutics; Corcept Therapeutics Inc.; Crinetics Pharmaceuticals; H. Lundbeck A/S; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals; Novo Nordisk; PhaseBio Pharmaceuticals, Inc.; Quest Diagnostics; Recordati Rare Diseases; Takeda Development Center Americas, Inc.; Xeris Pharmaceuticals
Contracted researcher for: Corcept Therapeutics Inc.; Diurnal Ltd.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals; Sparrow Pharmaceuticals; Spruce Biosciences
Patricia Fechner, MD
Medical Director, DSD Program
Medical Director, CAH Program
Co-Director, Turner Syndrome Clinic
Seattle Children’s Hospital
Professor of Pediatrics
University of Washington School of Medicine
Seattle, WA
Stock ownership: Abbott Laboratories, Abbvie
Member of advisory board: Neurocrine Biosciences
Principal Investigator: Neurocrine Biosciences, Spruce Bioscience and Lumos
Consultant: Easton Pharmaceuticals
Ellen Seely, MD
Vice Chair, Faculty Development
Department of Medicine
Director of Clinical Research, Endocrinology, Diabetes and Hypertension Division
Brigham & Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA
Scientific and Clinical Advisory Boards: Adrenas Therapeutics
Data Safety Monitoring Board: Neurocrine Biosciences
Phyllis W. Speiser, MD
Associate Professor, Institute of Molecular Medicine
Feinstein Institutes for Medical Research
Emerita Professor, Pediatrics Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
New Hyde Park, NY
Consultant or advisor for: Adrenas Therapeutics
Research funding from: Neurocrine Biosciences, Inc.
Perrin White, MD
Chief, Division of Pediatric Endocrinology
Audre Newman Rapoport Distinguished Chair in Pediatric Endocrinology
UT Southwestern Medical Center
Dallas, TX
Consultant: Neurocrine Biosciences
Program Managers and Web Editor Disclosure
Program Managers Gideon Bosker, MD and Denise Leary have nothing to disclose.
Educational Objectives
Upon completion of this activity, participants will be able to:
- Characterize the disease burden and pathophysiology of congenital adrenal hyperplasia, or CAH, as one of a spectrum of genetic conditions that affect the adrenal glands.
- Distinguish between classic CAH, a rare, more severe form of the disorder identified at birth, causing a complex of symptoms affecting multiple organs, from other less severe genetic variants of CAH
- Understand the significant challenges to long-term management and optimal titration of pharmacologic therapies that represent current standard of care for CAH
- Detail the pharmaco-physiology, targets, unmet need for, and potential advantages of several novel non-glucocorticoid treatment approaches under investigation that target the underlying pathophysiological mechanisms of congenital adrenal hyperplasia
- Review the potential clinical applications of evolving, potentially novel treatments—among them, CRHR1 receptor antagonists, anti-ACTH monoclonal antibodies, antiandrogens, aromatase inhibitors, abiraterone acetate, and mitotane—that aim to limit the exposure to adrenal androgen excess
- Outline the pathophysiology of approaches that inhibit CRF1 and related targets at upstream nodal points of the HPA axis, thereby providing bi axial inhibition of downstream glucocorticoid and mineralocorticoid secretion and, by extension, permitting lower, non-HPA axis suppressing doses of glucocorticoid for clinical management of CAH
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
Privacy Policy
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
- You should check this privacy policy periodically to see whether we have made any changes.
Disclaimer
Copyright © 2024 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.